807MO High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients

• DOI: 10.1016/j.annonc.2024.08.858
• Publication Date: 2024-09-17T20:13:00Z
• Authors: L. Yu; L. Kang; S. Xue; X. Tang; X. Lou; C. Qian; W. Gong; M. Xu; H. Zhou; Z. Yao; W. Wang; M. Li; N. Xu; Z. Yu; S. Chen; H. Qiu; H. Dai; Y. Xu; D. Wu